Fulcrum Therapeutics (FULC) is in the spotlight after halting development of its sickle cell drug pociredir, following FDA concerns about malignancy risks with PRC2 inhibitors and launching a broad review of future options.

The recent pociredir halt and review of future options have coincided with intense selling pressure, with the 7 day share price return down 52.5% and the year to date share price return down 70.5%. The 3 year total shareholder return is slightly positive, suggesting long term holders have experienced a very different journey to recent entrants.

If this kind of sudden biotech reset has you reassessing your watchlist, it could be worth broadening your search with the 40 healthcare AI stocks

With Fulcrum now trading at $3.22 after sharp recent declines, a suspended rating from at least one major bank, and a large cash balance on the books, you have to ask: is this a reset buying opportunity, or is the market already pricing in whatever growth comes next?

Most Popular Narrative: 83.1% Undervalued

Against a last close of $3.22, the most followed narrative pegs Fulcrum Therapeutics' fair value much higher, framing today's sell off as a deep discount.

The Phase 1b PIONEER data for pociredir in severe sickle cell disease show consistent HbF induction in all evaluable patients, with mean HbF of 19.3% at week 12 and more than half of patients at or above 20%. This can support future pricing power and potential revenue if later stage trials are successful and the product is approved.

Want to understand why this narrative still supports a much higher fair value? It focuses on long term revenue ramp, margin uplift and a rich future earnings multiple.

Result: Fair Value of $19 (UNDERVALUED)

However, this hinges on pociredir clearing safety questions and regulators accepting the trial design and endpoints, either of which could still derail the bullish setup.

Another View: Cash Flows Point To A Very Different Story

While the popular narrative leans on analyst targets and future earnings, the Simply Wall St DCF model tells a cooler story. On this measure, Fulcrum is trading at $3.22, above an estimated future cash flow value of $2.19, which screens as overvalued rather than discounted.

That kind of gap can matter, because it suggests a lot of hope is already in the price even after the recent sell off. The question is whether you trust the cash flow math or the long term narrative more.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Fulcrum Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If you are unconvinced by either story so far, or feel the clock is ticking after such a sharp move, it may help to scrutinize the risk profile yourself and begin with the 4 important warning signs.

Looking for more investment ideas?

If this kind of stock specific shock has you rethinking where you put fresh capital, it is a smart moment to widen your hunt for stronger ideas.

• Zero in on potential mispricings by scanning the 45 high quality undervalued stocks that pair solid fundamentals with attractive entry points.
• Strengthen your focus on resilience by reviewing the 65 resilient stocks with low risk scores that score well on financial and risk checks.
• Get ahead of the crowd by searching the screener containing 22 high quality undiscovered gems before they land on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.